Table 3.
Average testosterone, SHBG, and measures of obesity in men treated with atorvastatin split into two groups: those treated with 10 mg and those treated with 20 mg or more
| No statin | Atorvastatin |
||||
|---|---|---|---|---|---|
| 10 mg | P value | ≥20 mg | P value | ||
| n | 186 | 38 | 14 | ||
| Total testosterone (nmol/l) | 13.4 | 11.9 | 0.102 | 9.63 | 0.017 |
| Bioavailable testosterone (nmol/l) | 4.14 | 3.8 | 0.197 | 3.71 | 0.598 |
| Free testosterone (nmol/l) | 0.284 | 0.257 | 0.129 | 0.249 | 0.538 |
| SHBG (nmol/l) | 35.3 | 30.1 | 0.322 | 21.7 | 0.043 |
| Waist circumference (cm) | 109.8 | 111.4 | 0.5 | 115 | 0.829 |
| BMI (kg/m2) | 32.47 | 33.19 | 0.348 | 34.87 | 0.0.755 |
| Total cholesterol (mmol/l) | 5.04 | 4.55 | 0.003 | 4.82 | 0.224 |
The 10-mg atorvastatin group was compared with the no statin group with Student's t test; significant results are shown in boldface. The ≥20-mg atorvastatin group was compared with the no statin group using a two-sample Kolmogorov-Smirnov test. There is a trend toward lower total testosterone and SHBG levels in men taking the higher doses of atorvastatin, but this does not reach statistical significance.